Novo Signs $2 Billion Deal With United Labs for Obesity Drug
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...
TipRanks on MSN11d
United Laboratories’ Liraglutide Injection Gains NMPA Approval
The United Laboratories International Holdings ( ($HK:3933) ) has issued an update. The United Laboratories International Holdings Limited ...
Reuters9d
Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech
March 24 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab has bought global rights to China-based United Laboratories International's (3933.HK), opens new tab so-called "triple ...
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.
PharmExec7d
Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist
Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...
The United Laboratories International Holdings Limited (OTCMKTS:ULIHF) Short Interest Update
The United Laboratories International Holdings Limited (OTCMKTS:ULIHF – Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 28th, ...
Jefferies Sticks to Their Buy Rating for The United Laboratories International Holdings (ULIHF)
In a report released yesterday, David Shang from Jefferies maintained a Buy rating on The United Laboratories International Holdings (ULIHF – ...
Yahoo Finance8d
Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech
(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.